Merck snaps up a German immuno-oncology upstart in a $603M bolt … – Endpoints News

Posted: September 7, 2017 at 12:44 pm

Munich-based Rigontec is delivering a solid return for its venture backers. Merck $MRK has struck a rare deal to buy the biotech for $150 million in cash and another $453 million in milestones, snapping up a 3-year-old fledgling that raised just 30 million to get to this point.

For Merck its another example of how Roger Perlmutter likes to augment the work being done around its PD-1 superstar Keytruda with the occasional add-on. Its a small deal for the pharma giant, and hes clearly impressed with the potential the Bonn University spinout has in activating RIG-I as a key pathway in the innate immune system.

The technology is designed to activate an immune response, just as PD-1 can eliminate a defensive network protecting cancer cells.

Rigontecs immuno-oncology approach of engaging the innate immune system to safely eliminate cancer cells complements our strategy and our current pipeline, said Eric Rubin, vice president of early-stage oncology development at Merck Research Laboratories. We are eager to build upon Rigontecs science as we continue our efforts in bringing forward meaningful advances for patients with cancer.

Merck under Perlmutter has struck a few of these small acquisitions. IOmets I/O work was bagged in mid-2016 in another easy bolt-on for Merck, which hasnt been doing big deals in recent years.

The big winners today are Rigontecs investors:Boehringer Ingelheim Venture Fund, Forbion Capital Partners, High-Tech Grnderfonds, MP Healthcare Venture Management, NRW.BANK, Sunstone Capital and Wellington Partners Life Sciences.

Full-text daily reports for those who discover, develop, and market drugs. Join 18,000+ biopharma pros who read Endpoints News by email every day.

Read more:
Merck snaps up a German immuno-oncology upstart in a $603M bolt … – Endpoints News

Related Post